Laurenz Maren, von Eiff Christof, Borchert Kathrin, Jacob Christian, Seidel Karolin, Schley Katharina
Pfizer Pharma GmbH, Linkstraße 10, 10785 Berlin, Germany.
Xcenda GmbH, Lange Laube 31, 30159 Hannover, Germany.
Vaccine. 2021 Dec 17;39(51):7387-7393. doi: 10.1016/j.vaccine.2021.11.002. Epub 2021 Nov 28.
In 2015, the German Standing Committee on Vaccination (STIKO) changed the pneumococcal conjugate vaccination (PCV) schedule for mature infants from a 3+1scheme (2, 3, 4, and 11-14 months of age) to a 2+1scheme (2, 4, and 11-14 months of age). For premature infants, the 3+1scheme remained. The aim of this study was to assess vaccination rates, completeness, and timeliness for PCV in premature infants before and after the modified recommendation.
A retrospective claims data analysis using the "Institut für angewandte Gesundheitsforschung Berlin" Research Database was conducted. Premature infants born in 2013 and 2016 with an individual follow-up of 24 months were included. Hexavalent combination (HEXA) vaccination with a consistent 3+1recommendation for mature and premature infants was analyzed as reference vaccination.
After 24 months, the PCV rate for at least one dose remained stable in premature newborns of 2016 compared to 2013, while the HEXA vaccination rate increased slightly. However, a significant decrease of a completed PCV schedule (4 doses) in premature infants was noted, whereas the completeness of HEXA vaccination did not change. The timeliness of PCV in premature newborns increased for the first and the booster PCV, while the timeliness of HEXA immunization did not change from 2013 to 2016.
Although STIKO still recommends a 3+1PCV schedule for premature infants in Germany, premature infants were vaccinated according to the changed recommendations for mature born infants. A substantial share of premature infants remained unvaccinated, and their vaccinations were often delayed.
2015年,德国疫苗接种常设委员会(STIKO)将成熟婴儿的肺炎球菌结合疫苗(PCV)接种程序从3+1方案(2、3、4月龄以及11-14月龄)改为2+1方案(2、4月龄以及11-14月龄)。对于早产儿,仍采用3+1方案。本研究的目的是评估修改建议前后早产儿PCV的接种率、全程接种率和及时性。
利用“柏林应用健康研究机构”研究数据库进行回顾性索赔数据分析。纳入2013年和2016年出生且个体随访24个月的早产儿。将对成熟和早产儿均一致推荐3+1方案的六价联合疫苗(HEXA)接种作为对照疫苗进行分析。
24个月后,与2013年相比,2016年早产新生儿至少接种一剂PCV的比例保持稳定,而HEXA疫苗接种率略有上升。然而,早产儿完成PCV全程接种(4剂)的比例显著下降,而HEXA疫苗接种的全程接种率没有变化。早产新生儿首剂和加强剂PCV接种的及时性有所提高,而从2013年到2016年,HEXA免疫接种的及时性没有变化。
尽管德国STIKO仍建议对早产儿采用3+1PCV接种程序,但早产儿是按照针对足月儿的修改建议进行接种的。相当一部分早产儿仍未接种疫苗,且他们的接种往往延迟。